Vernakalant
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Vernakalant: From Atrial Fibrillation Cardioversion to Stroke Disorder
One-Sentence Summary
Vernakalant is an atrial-selective antiarrhythmic agent used for the acute pharmacological cardioversion of atrial fibrillation (AF). The TxGNN model predicts it may be effective for Stroke Disorder, but the supporting evidence — 3 clinical trials and 7 publications — addresses AF cardioversion outcomes rather than stroke prevention directly, so this is best framed as an indirect, mechanistically plausible hypothesis rather than a validated new indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not formally licensed in this dataset; known clinical use is acute pharmacological cardioversion of atrial fibrillation (AF), based on trial and literature context |
| Predicted New Indication | Stroke Disorder |
| TxGNN Prediction Score | 99.83% |
| Evidence Level | L4 |
| EU Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed, formally sourced mechanism-of-action data is not available for vernakalant in this Evidence Pack (flagged as a High-severity data gap). However, based on the trial and literature context collected, vernakalant is known to act as an atrial-selective sodium/potassium ion channel blocker, used to convert atrial fibrillation to sinus rhythm (“pharmacological cardioversion”).
The link between AF and stroke is well established: AF is one of the most important risk factors for ischemic stroke, since disorganized atrial contraction promotes thrombus formation and embolization. Restoring sinus rhythm is therefore hypothesized to reduce thromboembolic risk over time, which is the biological rationale the TxGNN model appears to be capturing.
However, this is an indirect mechanistic link — vernakalant treats the upstream arrhythmia (AF), not stroke itself, and none of the identified trials used stroke incidence, thromboembolic events, or neurological outcomes as a primary or secondary endpoint. All three related trials were graded “B” relevance (AF cardioversion efficacy vs. comparator drugs), meaning the connection to stroke prevention remains theoretical rather than clinically demonstrated.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01447862 | Phase 4 | Completed | 101 | Vernakalant vs. ibutilide for cardioversion of recent-onset AF; evaluates conversion success, not stroke outcomes (relevance grade B) |
| NCT01646281 | Phase 4 | Unknown | 70 | Compared vernakalant and flecainide on atrial contractility post-cardioversion, a factor linked to post-cardioversion stroke risk; did not track actual stroke events, and trial status is unverified |
| NCT04485195 | Phase 4 | Completed | 350 | RAFF4 trial: IV vernakalant vs. IV procainamide for acute AF in the emergency department; endpoint was cardioversion success/speed/safety, not stroke prevention |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 27292602 | 2016 | Cohort | The American Journal of Emergency Medicine | Single-center cohort on safety/efficacy of pharmacological cardioversion for recent-onset AF, including 30-day thromboembolism and mortality tracking |
| 22166900 | 2012 | Review | Lancet | General review of AF management, stroke risk stratification, and anticoagulation strategy; mentions vernakalant as an emerging antiarrhythmic option |
| 17371199 | 2007 | Pharmacology Review | Expert Opinion on Investigational Drugs | Summarizes vernakalant’s mechanistic properties as an atrial-selective antifibrillatory agent and its development for AF conversion, noting stroke as a downstream complication of AF |
| 22576674 | 2012 | Review | Current Hypertension Reports | Reviews recent AF trials in hypertensive patients, referencing vernakalant’s efficacy/safety and AF’s role as a major stroke risk factor |
| 23553811 | 2013 | Review | Pharmacotherapy | Clinical update on AF management strategies, including rhythm vs. rate control and antiarrhythmic options such as vernakalant |
| 19678722 | 2009 | Review | Journal of Managed Care Pharmacy | Reviews established and emerging pharmacologic AF management options, positioning vernakalant among newer conversion agents |
| 25024989 | 2014 | Review | Heart, Lung and Vessels | Year-in-review of cardiothoracic/vascular anesthesia advances, including AF pharmacotherapy and stroke-reduction interventions |
EU Market Information
Vernakalant currently has no active marketing authorization recorded in this dataset (market status: Not marketed; 0 authorizations on file). No product-level licensing details are available for review.
Safety Considerations
Please refer to the SmPC for safety information. Key warnings, contraindications, and drug-drug interaction data are not currently available in this dataset; a formal review of the product label is required before any further safety evaluation.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The mechanistic link to stroke is indirect — vernakalant acts on the upstream condition (AF), and no identified trial or publication uses stroke incidence, thromboembolism, or neurological outcomes as an endpoint (evidence level L4, all trial relevance graded B).
- A Blocking-severity data gap on warnings/contraindications currently prevents even an initial (S1) safety assessment, and the drug has no active EU marketing authorization to anchor a repurposing pathway.
To proceed, the following is needed:
- Resolve the Blocking data gap: obtain formal product label warnings and contraindications (source: regulatory label PDF) to enable an S1 safety screen
- Confirm detailed mechanism of action via DrugBank or equivalent primary source
- Identify or design studies with stroke/thromboembolic events as a direct endpoint following vernakalant-induced cardioversion (current evidence only supports AF conversion efficacy, not stroke outcomes)
- Clarify current EU regulatory/marketing status, since 0 active authorizations limits near-term repurposing feasibility
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.